<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336127">
  <stage>Registered</stage>
  <submitdate>20/10/2010</submitdate>
  <approvaldate>28/10/2010</approvaldate>
  <actrnumber>ACTRN12610000917033</actrnumber>
  <trial_identification>
    <studytitle>Post-prandial lipid effects of ritonavir-boosted atazanavir vs ritonavir-boosted darunavir in HIV-uninfected adults</studytitle>
    <scientifictitle>To compare the effects of ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg once daily) to ritonavir-boosted darunavir (DRV 800mg / RTV 100mg once daily) over 4 weeks on postprandial lipids in healthy volunteers.</scientifictitle>
    <utrn>U1111-1117-5291</utrn>
    <trialacronym>rAD</trialacronym>
    <secondaryid>rAD</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>post prandial lipid disturbances associated with Atazanavir-Ritonavir vs Darunavir-Ritonavir</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To compare the effects of oral ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg once daily) to oral ritonavir-boosted darunavir (DRV 800mg / RTV 100mg once daily) over 4 weeks.</interventions>
    <comparator>oral tablets ritonavir-boosted darunavir (DRV 800mg / RTV 100mg once daily) over 4 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the effects of ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg once daily) to ritonavir-boosted darunavir (DRV 800mg / RTV 100mg once daily) over 4 weeks on postprandial lipids in healthy volunteers.</outcome>
      <timepoint>Blood measurements at screening visit, baseline and week 4 at timepoints:premeal, post meal 1 hr, 2 hrs, 3 hrs and 4 hrs. 
Blood measurements are collected at week 2 once.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the effects of ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg once daily) to ritonavir-boosted darunavir (DRV 800mg / RTV 100mg once daily) over 4 weeks on:
safety</outcome>
      <timepoint>liver function tests are performed at screening visit, baseline and week 4 at timepoints:premeal, post meal 1 hr, 2 hrs, 3 hrs and 4 hrs.
these blood tests are collected at week 2 once.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>glycaemic responses</outcome>
      <timepoint>glucose and insulin measurements at screening visit, baseline and week 4 at timepoints:premeal, post meal 1 hr, 2 hrs, 3 hrs and 4 hrs.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reactive protein and D-dimer</outcome>
      <timepoint>C-reactive protein and D-dimer measurements at baseline and week 4 visits at timepoints:premeal, post meal 2 hrs and 4 hrs. 
Blood measurements are also collected at week 2 once.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>aterial stiffness</outcome>
      <timepoint>measured by performing radial artery tonomerry at baseline and week 4 at timepoints:premeal, post meal 1 hr, 2 hrs, 3 hrs and 4 hrs. 
also measured at week 2.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Provision of signed, informed consent
2.Adults taking their normal diet (stable intake for each participant) with a stable weight and no desire to lose or gain weight
3.Body mass index between 20 and 30 kg/m2
4.Fasting triglycerides &lt; 2.0 mmol/l
5.Fasting total cholesterol &lt; 6.0 mmol/l</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>6.HIV infection (antibody, western blot, proviral DNA)
7.Use of any medication contra-indicated with RTV, AZV or DRV
8.Use of lipid-lowering therapy
9.Use of anti-hypertensive therapy
10.Diabetes mellitus (fasting glucose &gt; 7.0 mmol/l or a prior diagnosis of diabetes)
11.Serum hepatic transaminases (ALT / AST) greater than 3 times the upper limit of normal
12.Pregnancy or breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>This is a randomized, open-label, 4-week trial. Twenty (20) eligible participants will be randomly allocated 1:1 to receive:
i) ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg) once daily for four (4) weeks 
OR
ii) ritonavir-boosted darunavir (DRV 800mg / RTV 100mg) once daily for four (4) weeks


Method of allocation to the above is conducted by a blinded 'third party' using sealed opaque envelopes using the method of 'block randomisation'.</concealment>
    <sequence>Treatment allocation will be randomised according to the method of “block randomisation” to balance the number of patients recruited in each treatment arm.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate>12/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>14/12/2011</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St vincents Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria St,
Darlinghurst, NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, open-label, 4-week trial. Twenty (20) eligible participants will be randomly allocated 1:1 to receive:

i)	ritonavir-boosted atazanavir (AZV 300mg / RTV 100mg) once daily for four (4) weeks 
OR
ii)	ritonavir-boosted darunavir (DRV 800mg / RTV 100mg) once daily for four (4) weeks

Planned sample size: Twenty (20) eligible participants who complete the 4 week study
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor andrew Carr</name>
      <address>St Vincents Centre for Applied Medical Research 
Clinical Research Program
Level 4, Xavier Building
390 Victoria St
Darlinghurst
NSW 2010</address>
      <phone>+61 2 8382 3438</phone>
      <fax>+61 2 8382 2090</fax>
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nicola Mackenzie</name>
      <address>St Vincents Centre for Applied Medical Research 
Clinical Research Program
Level 4, Xavier Building
390 Victoria St
Darlinghurst
NSW 2010</address>
      <phone>+61 2 8382 2919</phone>
      <fax>+61 2 8382 3869</fax>
      <email>nmackenzie@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robyn Richardson</name>
      <address>St Vincents Centre for Applied Medical Research 
Clinical Research Program
Level 4, Xavier Building
390 Victoria St
Darlinghurst
NSW 2010</address>
      <phone>+61 2 8382 3872</phone>
      <fax>+61 2 8382 3869</fax>
      <email>rrichardson1@stvincents.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Carr</name>
      <address>St Vincents Hospital
Xavier, Level 4, 390 victoria St
Darlinghurst, NSW, 2010</address>
      <phone>+61 2 83823359</phone>
      <fax />
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>